Autologous Stem-Cell Transplantation Without Hematopoietic Support for the Treatment of Hematologic Malignancies in Jehovah’s Witnesses. Ford PA et al. J Clin Oncol. 2015 Apr 13. pii: JCO.2014.57.9912. [Epub ahead of print]. Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosedmultiple myeloma patients with severe renal impairment. Zannetti BA et al. Am J Hematol. 2015 Apr 8. doi: 10.1002/ajh.24035.…
Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition. Stetler-Stevenson M et al. Cytometry B Clin Cytom. 2015 Apr 23. doi: 10.1002/cyto.b.21249. [Epub ahead of print]. Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma. Cejalvo MJ et al. Future Oncol. 2015 Apr 10:1-16. [Epub ahead of print]. Lenalidomide in multiple myeloma. Kim Y et al. Expert Rev Anticancer Ther. 2015 May;15(5):491-7. doi: 10.1586/14737140.2015.1033407.…
Thromboelastography, thrombin generation test and thrombodynamics reveal hypercoagulability in patients with multiple myeloma. Gracheva MA et al. Leuk Lymphoma. 2015 Apr 24:1-35. [Epub ahead of print]. Neurotoxicity of stem cell mobilization chemotherapy with vinorelbine in myeloma patients after bortezomib treatment. Keller S et al. Leuk Res. 2015 Mar 28. pii: S0145-2126(15)00086-7. doi: 10.1016/j.leukres.2015.03.015. [Epub ahead of print]. Subcutaneous bortezomib in multiple myeloma patients induces similar…
Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: Interim analysis from the prospective GMMG-MM5 trial. Merz M et al. Haematologica. 2015 Apr 3. pii: haematol.2015.124347. [Epub ahead of print]. Autologous stem cell transplantation versus novel drugs or conventional chemotherapy for patients with relapsed multiple myeloma after previous ASCT. Grövdal M et al. Bone Marrow Transplant. 2015 Apr 13.…
Data from MUK one, the first trial to be conducted through the Myeloma UK Clinical Trial Network (CTN) have been published in the British Journal of Haematology. MUK one, a Phase II multicentre, open label, randomised trial aimed to identify the optimal starting dose of bendamustine when given in combination with thalidomide and dexamethasone in relapsed…
Data from MUK one, the first trial to be conducted through the Myeloma UK Clinical Trial Network (CTN) has been published in the British Journal of Haematology. The publication represents a major milestone for the CTN by marking the completion of its first trial. MUK one, a Phase II multicentre, open label, randomised trial aimed…
Bortezomib is recommended as induction treatment in combination with dexamethasone, or with dexamethasone and thalidomide, for previously untreated myeloma patients who are eligible for high-dose chemotherapy and haematopoietic stem cell transplantation.
European Organisation for Research and Treatment of Cancer (EORTC) assessment of quality of life of myeloma patients.
Bortezomib monotherapy is recommended as an option for myeloma patients who have relapsed after having received one prior treatment and who have undergone, or are not eligible for high-dose chemotherapy and stem cell transplantation.
Lenalidomide in combination with dexamethasone is recommended, within its licensed indication, as an option only for myeloma patients who have received two or more prior treatments on the condition that the drug cost for patients who remain on treatment for more than 26 cycles is met by the manufacturer.
